Akari Therapeutics (AKTX) Depreciation & Amortization (CF) (2014 - 2024)
Akari Therapeutics (AKTX) reported Depreciation & Amortization (CF) of $1000.0 for Q4 2024, little changed on a YoY basis from $1000.0 in Q1 2024, and down 92.31% sequentially from $13000.0 in Q1 2024.
Akari Therapeutics (AKTX) Depreciation & Amortization (CF) (2014 - 2024) Analysis & Trends
Akari Therapeutics (AKTX) has 7 years of Depreciation & Amortization (CF) data on file, last reported at $1000.0 in Q4 2024.
- For the quarter ending Q4 2024, Depreciation & Amortization (CF) changed 0.0% year-over-year to $1000.0; the trailing twelve-month figure through Sep 2025 stood at $1000.0 (down 92.86% YoY), and the FY2024 full-year result was $14000.0, up 250.0% from the prior year.
- Depreciation & Amortization (CF) slipped to $1000.0 in Q4 2024, from $13000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $13000.0 in Q1 2024 to a low of $986.0 in Q3 2020.
- A 3-year average of $2690.7 and a median of $1000.0 in 2020 frame the typical range for Depreciation & Amortization (CF).
- Across the five-year window, Depreciation & Amortization (CF) slumped 78.69% in 2020 and soared 1200.0% in 2024, its largest moves.
- Tracing AKTX's Depreciation & Amortization (CF) over 3 years: stood at $1000.0 in 2020, then changed by 0.0% to $1000.0 in 2023, then changed by 0.0% to $1000.0 in 2024.
- Business Quant data shows AKTX's Depreciation & Amortization (CF) at $1000.0 in Q4 2024, $13000.0 in Q1 2024, and $1000.0 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,000.00 |
| Dec 31, 2024 | 1,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Mar 31, 2024 | 13,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Dec 31, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Sep 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Jun 30, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Mar 31, 2023 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Dec 31, 2020 | 1,000.00 |
| Sep 30, 2020 | 986.00 |
| Sep 30, 2020 | 986.00 |
| Jun 30, 2020 | 3,044.00 |
| Jun 30, 2020 | 3,044.00 |
| Mar 31, 2020 | 3,877.00 |
| Mar 31, 2020 | 3,877.00 |